Sarepta Therapeutics (SRPT) Long-Term Investments (2013 - 2026)

Sarepta Therapeutics' Long-Term Investments history runs 14 years deep, the most recent figure standing at $270.7 million for Q1 2026.

• In Q1 2026, Long-Term Investments rose 148.06% year-over-year to $270.7 million; the TTM figure through Mar 2026 stood at $270.7 million (up 148.06% YoY), while the FY2025 annual figure was $1.0 million, down 99.21% from the prior year.
• Long-Term Investments for Q1 2026 stood at $270.7 million, up from $1.0 million in the prior quarter.
• The five-year high for Long-Term Investments was $324.1 million in Q2 2025, with the low at $1.0 million in Q4 2025.
• The 5-year median for Long-Term Investments is $31.0 million (2023), against an average of $62.6 million.
• Peak annual rise in Long-Term Investments reached 4161.11% in 2025, while the deepest fall reached 99.21% in 2025.
• Sarepta Therapeutics' Long-Term Investments stood at $31.3 million in 2022, then tumbled by 79.16% to $6.5 million in 2023, then surged by 1940.19% to $133.2 million in 2024, then plunged by 99.21% to $1.0 million in 2025, then soared by 25730.15% to $270.7 million in 2026.
• Business Quant data shows SRPT's Long-Term Investments at $270.7 million in Q1 2026, $1.0 million in Q4 2025, and $8.2 million in Q3 2025.